Move to sell statins over the counter raises concernsBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7450.1221-b (Published 20 May 2004) Cite this as: BMJ 2004;328:1221
- Liza Gibson
Doctors' leaders and consumer bodies have raised concerns about the UK government's decision to allow the cholesterol lowering agent, simvastatin, to become available without prescription in pharmacies.
The reclassification, announced last week by the Department of Health to increase patients' choice and to help reduce coronary heart disease, will be the world's first for a statin. About 1.8 million people in England are prescribed statins, costing the NHS around £700m ($1200m; €1000m) a year. Some £309m is spent on simvastatin alone.
The over the counter product, to be called Zocor Heart-Pro (10 mg), will be aimed at …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial